相关实验视频
Updated: May 20, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
在1型糖尿病患者中使用葡萄糖的障碍
Emma Mason1, Kagan E Karakus1, Halis K Akturk1
1Barbara Davis Center for Diabetes, University of Colorado, United States.
Primary care diabetes
|March 23, 2025
概括
在患有1型糖尿病的成年人中,在严重低血糖期间,葡萄糖的使用率较低. 这项研究确定了使用葡萄糖的障碍,并提出了改善其在紧急情况下的管理的解决方案.
科学领域:
- 内分泌学 在内分泌学.
- 糖尿病管理 糖尿病管理
- 紧急医疗 紧急医疗
背景情况:
- 严重的低血糖是1型糖尿病患者的关键并发症.
- 在严重的低血糖事件中,目前的葡萄糖激素利用率低于最佳水平.
- 了解使用葡萄糖激素的障碍对于改善患者安全至关重要.
研究的目的:
- 调查阻碍1型糖尿病成年人有效使用葡萄糖的障碍.
- 确定患者和护理人员在严重低血糖症期间遇到的具体挑战.
- 为制定提高葡萄糖的可访问性和管理的策略提供信息.
主要方法:
- 在576名被诊断为1型糖尿病的成年人中进行了一项调查.
- 数据收集集中在与低血糖期间使用葡萄糖相关的经验和看法.
- 使用统计分析来识别重大障碍.
主要成果:
- 确定了几种对葡萄糖剂的关键障碍,包括:
- 缺乏培训,对施用的恐惧,以及对葡萄糖疗效的担忧是突出的.
- 据报道,对葡萄糖激素装置的有限访问也是一个重大问题.
结论:
- 在1型糖尿病中使用葡萄糖的障碍是多方面的,包括知识,信心和访问.
- 通过教育和改善接入来解决这些障碍,对于减轻严重低血糖的负担至关重要.
- 未来的干预措施应专注于赋予1型糖尿病患者及其支持网络的人权,让他们自信地使用葡萄糖.
相关概念视频
Hypoglycemia and Glucagon
143
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143
Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Oral Hypoglycemic Agents: Glinides
116
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
116
Hormones Regulating Blood Glucose
2.9K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
2.9K
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K

